|
1）石渡俊行, 松田陽子, 内藤善哉．膵臓癌におけるFGFシグナルの発現とその役割．肝胆膵．2010; 61: 73-9
|
|
|
|
2）Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-29
|
|
|
|
|
3）Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Durg discov. 2009; 8: 235-53
|
|
|
|
|
|
4）加藤茂明，関根圭輔．FGFシグナルによる器官形成の分子メカニズム．医学のあゆみ．2001; 199: 1035-9
|
|
|
|
|
|
5）Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66: 11271-8
|
|
|
|
|
6）Foqarty MP, Emmenegger BA, Grasfeder LL, et al. Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells. Proc Natl Acad Sci U S A. 2007; 104: 2973-8
|
|
|
|
|
|
7）Grose R, Fantl V, Werner S, et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007; 26: 1268-78
|
|
|
|
|
|
8）Taraboletti G, D’Ascenzo S, Borsotti P, et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol. 2002; 160: 673-80
|
|
|
|
|
|
9）Kumar R, Yoneda J, Bucana CD, et al. Reguration of distinct steps of angiogenrsis by different angiogenic molecules. Int J Oncol. 1998; 12: 749-54
|
|
|
|
|
|
10）Klein S, Giancotti FG, Presta M, et al. Basic fibroblast growth factor modurates integrin expression in microvascular endothelial cells. Mol Biol Cell. 1993; 4: 973-82
|
|
|
|
|
|
11）Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathpgenesis of lung cancer. Clin Cancer Res. 2008; 14: 614-22
|
|
|
|
|
|
12）Marek L, Ware KE, Frizsche A, et al. Fibroblast growth factor （FGF） and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009; 75: 196-207
|
|
|
|
|
|
13）Mukherjee J, DeSouza LV, Micallef J, et al. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII. Cancer Res. 2009; 69: 8545-54
|
|
|
|
|
|
14）Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS one. 2011; 6: e20351
|
|
|
|
|
|
15）Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010; 2: 64-93
|
|
|
|
|
|
16）Goeke F, Franzen A, Menon R, et al. Rationale for treatment of metastatic squamous cell carcinoma of lung using FGFR inhibitors. Chest. 2012; 142: 1020-6
|
|
|
|
|
|
17）Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005; 23: 7307-11
|
|
|
|
|
|
18）Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphis may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009; 124: 2880-5
|
|
|
|
|
|
19）Sasaki H, Okuda K, Kawano O, et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Res. 2008; 20: 1125-30
|
|
|
|
|
|
20）Kobayashi S, Boqqon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92
|
|
|
|
|
|
21）Enqelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-43
|
|
|
|
|
|
22）Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutatiot lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011; 6: 2011-7
|
|
|
|
|
|
23）Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141: 69-80
|
|
|
|
|
|
24）Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidemal growth factor receptor- mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol. 2011; 6: 1152-61
|
|
|
|
|
|
25）Ware KE, Marshall ME, Heasley LR, et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS one. 2010; 5: e14117
|
|
|
|
|
|
26）Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor （FGF） and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009; 75: 196-207
|
|
|
|
|
|
27）Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: triple angiokinase inhibitor with ; sustained receptor blocked and good antitumor efficacy. Cancer Res. 2008; 68: 4774-82
|
|
|
|
|
|
28）Roth GJ, Heckle A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinonses as triple angiokinase inhibitors and the discovery of the highly specific 6-methoxycarbonyl-substituted indolinone（BIBF1120）. J Med Chem. 2009; 52: 4466-80
|
|
|
|
|
|
29）Reck M, Kaiser R, Eschbach C, et al. A phase Ⅱ double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011; 22: 1374-81
|
|
|
|
|
|
30）Altorki N, Lane ME, Bauer T, et al. Phase Ⅱ proof-of-concept study of pazopanib monotherapy in treatment-naïve patients with stage Ⅰ/Ⅱ resectable non-small-cell lung cancer. J Clin Oncol. 2010; 28: 3131-7
|
|
|
|
|